Informe de análisis del tamaño, la cuota de mercado y las tendencias del mercado global de recolección de células: descripción general de la industria y pronóstico hasta 2033.

Tamaño del mercado de recolección de células

• El tamaño del mercado global de recolección de células se valoró en 4700 millones de dólares en 2025  y se espera que alcance  los 9530 millones de dólares en 2033 , con una tasa de crecimiento anual compuesta (CAGR) del 9,25 % durante el período de pronóstico.
• El crecimiento del mercado se debe en gran medida a la creciente demanda de terapias basadas en células, el aumento de la producción biofarmacéutica y la expansión de las actividades de investigación en medicina regenerativa y aplicaciones con células madre.
• Además, las crecientes inversiones en investigación biotecnológica y de ciencias de la vida, junto con la necesidad de tecnologías eficientes y escalables para la separación y recuperación de células, están consolidando los sistemas avanzados de recolección de células como herramientas esenciales en el bioprocesamiento moderno y la investigación clínica. Estos factores convergentes están acelerando la adopción de soluciones automatizadas y de alto rendimiento para la recolección de células, impulsando así significativamente el crecimiento de la industria.

Análisis del mercado de recolección de células

• La recolección de células, que abarca las tecnologías y los procesos utilizados para separar y recolectar células de los sistemas de cultivo para aplicaciones posteriores, es un paso crítico en la fabricación de productos biofarmacéuticos, la medicina regenerativa y la producción de terapias celulares y génicas debido a su impacto en el rendimiento, la pureza y la eficiencia general del proceso.
• La creciente demanda de soluciones para la recolección de células se debe principalmente a la rápida expansión de las terapias basadas en células, el aumento de la producción de productos biológicos y las crecientes inversiones en investigación con células madre e ingeniería de tejidos, junto con la necesidad de tecnologías de bioprocesamiento escalables y automatizadas.
• América del Norte dominó el mercado de recolección de células con la mayor participación en los ingresos, un 38,76 % en 2025, caracterizada por una infraestructura biofarmacéutica avanzada, una sólida financiación para la investigación y la presencia de empresas biotecnológicas líderes. Estados Unidos experimentó un crecimiento sustancial en ensayos clínicos y en la fabricación de terapias celulares a escala comercial, respaldado por avances regulatorios y colaboraciones estratégicas.
• Se prevé que la región de Asia-Pacífico sea la de mayor crecimiento en el mercado de recolección de células durante el período de pronóstico, debido a la expansión de los sectores de biotecnología, el creciente apoyo gubernamental a la investigación en ciencias de la vida y el aumento de las inversiones en capacidades de biofabricación.
• El segmento de sistemas automatizados de recolección de células dominó el mercado con una cuota del 41,8 % en 2025, impulsado por la creciente necesidad de procesamiento de alto rendimiento, menor riesgo de contaminación y mejor reproducibilidad en operaciones de cultivo celular a gran escala.

Alcance del informe y segmentación del mercado de recolección de células      

Tendencias del mercado de recolección de células

“Automatización e integración de sistemas cerrados en bioprocesamiento”

• Una tendencia significativa y en auge en el mercado global de recolección de células es la creciente adopción de tecnologías automatizadas y de sistema cerrado integradas con plataformas de bioprocesamiento avanzadas. Esta convergencia está mejorando significativamente la eficiencia operativa, la garantía de esterilidad y la escalabilidad en la fabricación basada en células.
• Por ejemplo, las soluciones automatizadas de recolección de células integradas con biorreactores de un solo uso de empresas líderes en ciencias de la vida permiten una separación y recuperación celular sin problemas, minimizando al mismo tiempo los riesgos de contaminación. Del mismo modo, se están incorporando sistemas cerrados de centrifugación y filtración en los flujos de trabajo de producción de terapia celular de principio a fin para optimizar el procesamiento posterior.
• La integración de la automatización en la recolección de células permite funciones como la monitorización del proceso en tiempo real, protocolos programables y una mayor reproducibilidad entre lotes. Por ejemplo, algunos sistemas avanzados utilizan controles basados ​​en sensores para optimizar el rendimiento y la viabilidad celular, reduciendo al mismo tiempo la intervención manual. Además, las capacidades de los sistemas cerrados ofrecen a los fabricantes la ventaja de mantener el cumplimiento de las Buenas Prácticas de Fabricación (BPF) y reducir los riesgos de contaminación cruzada durante la producción a gran escala.
• La perfecta integración de los sistemas de recolección de células con los equipos de bioprocesamiento previos y posteriores facilita el control centralizado de los flujos de trabajo de fabricación. Mediante interfaces digitales unificadas, los operadores pueden supervisar las condiciones de cultivo, los parámetros de recolección y los pasos de purificación, creando un entorno de producción más sincronizado y eficiente.
• Esta tendencia hacia soluciones de recolección más automatizadas, escalables y con control de contaminación está transformando radicalmente los estándares operativos en la fabricación de productos biofarmacéuticos y medicina regenerativa. En consecuencia, varios proveedores de equipos de biotecnología están desarrollando plataformas de recolección integradas, con soporte de IA, análisis de procesos mejorados y compatibilidad con instalaciones modulares de salas blancas.
• La demanda de sistemas automatizados y cerrados de recolección de células está creciendo rápidamente tanto en el sector de la investigación como en el de la biofabricación comercial, a medida que las organizaciones priorizan cada vez más la escalabilidad, el cumplimiento normativo y la calidad constante del producto.
• Además, la creciente digitalización y la implementación de prácticas de la Industria 4.0 en la biofabricación están impulsando la integración de análisis de datos y capacidades de monitoreo remoto en los sistemas de recolección de células, mejorando la transparencia operativa y la toma de decisiones.

Dinámica del mercado de recolección de células

Conductor

“Aumento de la demanda de terapias celulares y génicas y de producción de productos biológicos”

• La creciente prevalencia de enfermedades crónicas y la rápida expansión de los proyectos de terapia celular y génica, junto con el aumento de la fabricación de productos biológicos, son factores determinantes para la mayor demanda de tecnologías avanzadas de recolección de células.
• Por ejemplo, en los últimos años, varias empresas biofarmacéuticas han ampliado sus instalaciones de fabricación de terapias celulares a escala comercial , centrándose en la integración de sistemas de recolección automatizados para mejorar el rendimiento y mantener el cumplimiento normativo. Se espera que estas expansiones estratégicas por parte de los principales actores de la industria impulsen el crecimiento del mercado de recolección de células durante el período previsto.
• As healthcare systems emphasize precision medicine and regenerative therapies, efficient cell recovery processes become critical to ensuring high viability, purity, and consistency of therapeutic products, making advanced harvesting solutions a necessary upgrade over traditional manual techniques
• Furthermore, the increasing number of clinical trials in oncology, immunotherapy, and stem cell applications is making reliable cell harvesting a core component of end-to-end bioprocessing systems, encouraging greater investment in technologically advanced platforms
• The need for scalable production, reduced processing time, and improved batch-to-batch reproducibility are key factors propelling the adoption of automated and closed cell harvesting systems in both research institutions and commercial manufacturing environments. The trend toward modular biomanufacturing facilities and single-use technologies further contributes to market expansion
• In addition, growing government funding and private investments in biotechnology infrastructure are accelerating the establishment of advanced manufacturing facilities equipped with high-performance harvesting technologies
• The increasing focus on personalized medicine and autologous therapies is further driving demand for flexible and small-batch compatible cell harvesting solutions capable of handling patient-specific production workflows

Restraint/Challenge

“High Equipment Costs and Complex Regulatory Compliance Requirements”

• Concerns surrounding the high capital investment required for advanced automated harvesting systems, along with stringent regulatory compliance requirements, pose a significant challenge to broader market penetration. As cell harvesting equipment must meet strict GMP and quality standards, manufacturers face complex validation and documentation processes
• For instance, regulatory inspections and evolving compliance frameworks for cell and gene therapy production have increased operational scrutiny, making smaller biotechnology firms cautious about large-scale equipment investments
• Addressing these compliance and cost concerns through modular system designs, flexible financing models, and comprehensive validation support is crucial for wider adoption. Several leading suppliers emphasize their regulatory expertise, documentation packages, and technical support services to reassure potential buyers. In addition, the relatively high operational costs associated with maintenance, skilled labor, and process optimization can be a barrier for emerging biotech startups and academic research centers
• While technological advancements are gradually improving efficiency and lowering long-term operational expenses, the perceived financial and regulatory burden can still hinder widespread adoption, particularly in developing regions with limited biomanufacturing infrastructure
• Overcoming these challenges through cost-effective system innovations, streamlined regulatory pathways, and expanded technical training programs will be vital for sustained growth in the global cell harvesting market
• Moreover, variability in cell types and culture conditions across different therapeutic applications can complicate standardization, requiring customized harvesting protocols that increase operational complexity
• Limited availability of highly skilled bioprocessing professionals in certain regions may also restrict optimal utilization of advanced harvesting systems, thereby affecting productivity and return on investment

Cell Harvesting Market Scope

The market is segmented on the basis of type, application, end users, and distribution channel.

• By Type

On the basis of type, the global cell harvesting market is segmented into manual cell harvesters and automated cell harvesters. The automated cell harvesters segment dominated the market with the largest revenue share of 41.8% in 2025, driven by the increasing need for high-throughput processing, improved reproducibility, and reduced contamination risk in biopharmaceutical manufacturing. Automated systems offer programmable workflows, closed-system processing, and integration with upstream and downstream equipment, making them ideal for large-scale biologics and cell therapy production. Their ability to ensure GMP compliance and minimize human intervention significantly enhances operational efficiency. In addition, the growing number of commercial-scale cell therapy facilities has strengthened demand for advanced automated harvesting platforms. The reliability and scalability of automated systems position them as the preferred choice for industrial bioprocessing environments.

The manual cell harvesters segment is anticipated to witness the fastest growth rate during the forecast period, fueled by increasing adoption in small-scale laboratories, academic research institutes, and emerging biotechnology startups. Manual systems offer cost-effectiveness and operational flexibility, particularly for pilot-scale studies and early-stage research applications. They are suitable for customized harvesting protocols where experimental variability is required. Furthermore, limited capital budgets in developing regions encourage the adoption of manual solutions due to lower upfront investment. Continuous improvements in ergonomic design and efficiency are also enhancing their usability. The expanding number of research initiatives in regenerative medicine and stem cell studies is further contributing to segment growth.

• By Application

On the basis of application, the market is segmented into biopharmaceutical application, stem cell research, and others. The biopharmaceutical application segment dominated the market in 2025 due to the rapid expansion of biologics, monoclonal antibodies, vaccines, and cell and gene therapy production. Efficient cell harvesting is a critical step in ensuring high product yield and purity during large-scale manufacturing. The rising number of approved biologics and expanding clinical pipelines are significantly increasing demand for reliable harvesting technologies. In addition, stringent regulatory standards necessitate automated and contamination-free processes, supporting segment dominance. The presence of advanced manufacturing infrastructure in developed regions further strengthens this segment. Continuous investment in biomanufacturing capacity expansion is expected to sustain its leading position.

The stem cell research segment is projected to register the fastest growth rate from 2026 to 2033, driven by increasing focus on regenerative medicine, personalized therapies, and tissue engineering. Growing government funding and private investment in stem cell research programs are accelerating laboratory-scale cell processing activities. Efficient harvesting is crucial to maintain viability and functionality of stem cells for therapeutic applications. Rising clinical trials involving stem cell-based treatments are also expanding demand for advanced harvesting solutions. Academic collaborations and translational research initiatives further contribute to segment growth. The expanding role of stem cells in disease modeling and drug discovery is expected to boost this segment significantly.

• By End Users

On the basis of end users, the market is segmented into hospitals, research institutes, and community healthcare. The research institutes segment dominated the market with the largest share in 2025, attributed to extensive cell biology, oncology, and regenerative medicine research activities. These institutes frequently require harvesting systems for experimental and preclinical applications. Increased public and private funding for life sciences research has strengthened procurement of advanced laboratory equipment. Moreover, collaborations between academic institutions and biotechnology firms are driving demand for efficient harvesting technologies. The continuous expansion of research infrastructure globally further supports this segment’s leadership. High emphasis on innovation and discovery ensures sustained utilization of cell harvesting platforms in research settings.

The hospitals segment is expected to witness the fastest growth rate during the forecast period, driven by the increasing adoption of cell-based therapies and regenerative treatment procedures in clinical settings. As personalized medicine gains traction, hospitals are incorporating in-house cell processing capabilities to support therapeutic applications. Rising patient demand for advanced treatments such as immunotherapies is accelerating investment in cell handling technologies. Improvements in hospital-based laboratory infrastructure are further facilitating adoption. In addition, regulatory approvals of cell-based therapies are encouraging hospitals to integrate standardized harvesting systems. The shift toward point-of-care cell processing is anticipated to significantly boost this segment.

• By Distribution Channel

On the basis of distribution channel, the market is segmented into retail and direct tenders. The direct tenders segment dominated the market in 2025, primarily due to large-scale procurement by biopharmaceutical companies, research institutions, and hospitals. Bulk purchasing agreements enable organizations to acquire advanced harvesting systems with customized specifications and technical support services. Direct tender processes often include installation, validation, and long-term maintenance contracts, enhancing operational reliability. Government-funded research facilities and public healthcare institutions frequently rely on tender-based procurement mechanisms. The high cost of advanced automated systems further supports centralized purchasing strategies. This structured procurement model contributes significantly to segment dominance.

The retail segment is projected to witness the fastest growth rate from 2026 to 2033, driven by increasing demand from small and mid-sized laboratories and biotechnology startups. Retail channels provide easier access to modular and entry-level harvesting systems suitable for limited-scale operations. The expansion of online scientific equipment platforms is improving product accessibility and price transparency. Growing entrepreneurial activities in life sciences are encouraging decentralized equipment procurement. In addition, the availability of standardized, ready-to-install systems supports retail channel growth. As research activities diversify geographically, retail distribution is expected to gain substantial momentum.

Cell Harvesting Market Regional Analysis

• North America dominated the cell harvesting market with the largest revenue share of 38.76% in 2025, characterized by advanced biopharmaceutical infrastructure, strong research funding, and the presence of leading biotechnology companies
• Organizations in the region highly prioritize process efficiency, regulatory compliance, and product quality, leading to widespread adoption of automated and closed-system cell harvesting technologies integrated with upstream and downstream bioprocessing platforms
• This widespread adoption is further supported by well-established healthcare infrastructure, robust government and private research funding, and the presence of leading biotechnology and biopharmaceutical companies, positioning cell harvesting systems as essential components in both commercial manufacturing and advanced research application

U.S. Cell Harvesting Market Insight

The U.S. cell harvesting market captured the largest revenue share within North America in 2025, fueled by the rapid expansion of biopharmaceutical manufacturing and the growing number of cell and gene therapy clinical trials. Healthcare and biotechnology organizations are increasingly prioritizing scalable, automated harvesting systems to enhance production efficiency and regulatory compliance. The strong presence of leading biopharma companies, advanced research universities, and CDMOs further propels market growth. Moreover, continuous FDA approvals of biologics and regenerative therapies, along with substantial public and private research funding, are significantly contributing to the market's expansion.

Europe Cell Harvesting Market Insight

The Europe cell harvesting market is projected to expand at a substantial CAGR throughout the forecast period, primarily driven by increasing investments in biologics manufacturing and regenerative medicine research. The rise in chronic disease prevalence, coupled with expanding biotechnology infrastructure, is fostering the adoption of advanced cell harvesting technologies. European organizations are also focused on maintaining stringent GMP standards, encouraging the use of automated and closed-system solutions. The region is experiencing notable growth across research institutes and commercial manufacturing facilities, with harvesting systems being incorporated into both new bioprocessing plants and facility upgrades.

U.K. Cell Harvesting Market Insight

The U.K. cell harvesting market is anticipated to grow at a noteworthy CAGR during the forecast period, driven by expanding life sciences research and strong government support for biotechnology innovation. In addition, the country’s focus on advanced therapy medicinal products (ATMPs) is encouraging research centers and manufacturers to adopt efficient cell processing technologies. The U.K.’s well-established academic network and collaborative research environment are expected to continue stimulating market growth. Increasing partnerships between biotech startups and global pharmaceutical firms are further strengthening demand for advanced harvesting platforms.

Germany Cell Harvesting Market Insight

The Germany cell harvesting market is expected to expand at a considerable CAGR during the forecast period, fueled by the country’s robust biopharmaceutical sector and emphasis on high-quality manufacturing standards. Germany’s advanced industrial infrastructure and strong focus on precision engineering promote the adoption of technologically advanced harvesting systems. The integration of automated cell processing equipment within modular biomanufacturing facilities is becoming increasingly prevalent. Furthermore, the country’s commitment to research excellence and innovation supports growing demand for reliable and scalable cell harvesting solutions.

Asia-Pacific Cell Harvesting Market Insight

The Asia-Pacific cell harvesting market is poised to grow at the fastest CAGR during the forecast period of 2026 to 2033, driven by expanding biotechnology industries, rising healthcare investments, and increasing clinical research activities in countries such as China, Japan, and India. The region's growing focus on domestic biologics production, supported by favorable government initiatives, is accelerating the adoption of cell harvesting systems. Furthermore, as APAC strengthens its position as a global biomanufacturing hub, the affordability and accessibility of advanced cell processing technologies are expanding to a broader range of research and commercial facilities.

Japan Cell Harvesting Market Insight

The Japan cell harvesting market is gaining momentum due to the country’s strong focus on regenerative medicine, advanced healthcare infrastructure, and supportive regulatory framework for cell therapies. The Japanese market places significant emphasis on research quality and technological precision, driving the adoption of automated harvesting systems. The integration of cell harvesting technologies with advanced bioreactors and analytical platforms is fueling growth. Moreover, Japan’s proactive approach to commercializing stem cell therapies is likely to spur demand for efficient and compliant harvesting solutions across research and clinical sectors.

India Cell Harvesting Market Insight

The India cell harvesting market accounted for a significant market share in Asia Pacific in 2025, attributed to the country’s expanding biotechnology sector, increasing government funding, and rapid growth in pharmaceutical manufacturing. India stands as one of the emerging hubs for biologics and vaccine production, and cell harvesting technologies are becoming increasingly important in both research laboratories and commercial facilities. The push toward strengthening domestic biomanufacturing capabilities, alongside the rise of biotech startups and contract manufacturers, are key factors propelling the market in India.

Cell Harvesting Market Share

The Cell Harvesting industry is primarily led by well-established companies, including:

• Thermo Fisher Scientific Inc (U.S.)
• Sartorius AG (Germany)
• Miltenyi Biotec GmbH (Germany)
• Cytiva (U.S.)
• Beckman Coulter Ciencias de la Vida (EE. UU.)
• Terumo Blood and Cell Technologies, Inc. (EE. UU.)
• Grupo Esco Lifesciences (Singapur)
• PerkinElmer Inc. (EE. UU.)
• Danaher (EE. UU.)
• BD (EE. UU.)
• Bio-Rad Laboratories, Inc. (EE. UU.)
• Grupo Lonza AG (Suiza)
• Corning Incorporated (EE. UU.)
• STEMCELL Technologies Inc. (Canadá)
• CORPORACIÓN NIKON (Japón)
• PromoCell GmbH (Alemania)
• Alfa Laval Corporate AB (Suecia)
• PBS Biotech, Inc. (EE. UU.)
• Tomtec, Inc. (EE. UU.)
• Teleflex Incorporated (EE. UU.)

¿Cuáles son los últimos avances en el mercado global de recolección de células?

• En mayo de 2025, BioPharm International publicó un artículo sobre los avances en la automatización de la recolección de células, describiendo la integración ampliada de plataformas automatizadas de filtración de flujo tangencial (TFF) y centrifugación continua para mejorar la productividad, la reproducibilidad y la eficiencia de los procesos en los flujos de trabajo de biofabricación.
• En enero de 2025, Sphere Bio anunció el lanzamiento de Cyto-Mine® Chroma, una plataforma de análisis y aislamiento de células individuales de última generación que ofrece una multiplexación mejorada y una mayor flexibilidad en los ensayos para acelerar los flujos de trabajo de recolección y cribado celular de alto rendimiento en la investigación y el desarrollo de bioterapéuticos.
• En noviembre de 2024, Rousselot e IamFluidics presentaron un novedoso microportador soluble diseñado para optimizar el cultivo de células adherentes y mejorar significativamente la eficiencia de la recolección celular, al permitir una liberación más sencilla de las células de los microportadores para su uso posterior, algo fundamental para las terapias celulares y la producción de productos biológicos.
• En octubre de 2024, Sino-Biocan Biotechnology Ltd. lanzó el sistema automatizado, cerrado e integrado de procesamiento celular WUKONG, una plataforma totalmente automatizada diseñada para optimizar los flujos de trabajo de recolección y procesamiento celular, desde la extracción de sangre hasta el cultivo y la preparación del producto final, mejorando la eficiencia y reduciendo los riesgos de contaminación en entornos clínicos y biofarmacéuticos.
• En agosto de 2021, BioPharm International destacó los primeros beneficios de la automatización en la recolección de células, señalando innovaciones como la filtración en profundidad de un solo uso y las centrífugas automatizadas que reducen la contaminación y facilitan el procesamiento, lo que marca un cambio de las técnicas manuales al procesamiento automatizado de células.

SKU-20292